Michael Nohaile, Novartis Molecular Diagnostics, Featured at Biomarker Summit, Sept. 5th-7th, Zurich Michael Nohaile, Global Head of Novartis Molecular Diagnostics, will give a featured presentation on ‘The Biomarker is not the end – it’s just the beginning’ at GTC’s 2nd Biomarker Europe Summit (Sept
BigNews.Biz - Jul 31,2012 - Michael Nohaile, Global Head of Novartis Molecular Diagnostics, will give a featured presentation on ‘The Biomarker is Not the End – It’s Just the Beginning’ at GTC’s 2nd Biomarker Europe Summit (Sept 5th-7th, 2012 in Zurich, Switzerland)
What do drug discovery and translational scientists need to know to take their qualified biomarkers and turn them into marketable validated companion diagnostics? Sometimes it’s not what you know, but who you know. As drug discovery and translational scientists think about using stratification with biomarkers to improve the chances of getting medicines to patients, a number of areas of expertise need to be considered. Getting the right input from the right expert at the right time can make or break your effort to successfully bring a biomarker-based companion diagnostic into clinical practice. Dr Nohaile will give his perspective on what it takes to transform a biomarker into a commercial test.
Michael Nohaile, Ph.D., is the Head of Novartis Molecular Diagnostics. Previously at Novartis, Dr. Nohaile served as Head of Corporate Strategy and Pharma Strategy. He joined Novartis in 2007 from McKinsey & Company where he was a partner in the New Jersey office. At McKinsey, Dr. Nohaile worked extensively in the healthcare area with a particular focus on diagnostics and pharmaceuticals.
GTC’s 2nd Biomarkers Europe Summit will bring together leading experts across industry and academia to discuss the latest research and developments in the biomarker field, spanning across 3 disease areas: